Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Hematology ; 24(1): 331-336, 2019 Dec.
Article in English | MEDLINE | ID: mdl-30727851

ABSTRACT

OBJECT: To explore the critical role of growth differentiation factor 11 (GDF11) in the pathobiology of aplastic anemia (AA). METHODS: We have examined the serum GDF11 levels for 79 AA patients and 30 healthy controls. A total of 79 AA patients, which included 29 new diagnosed (untreated) cases, 14 cases with no response, 21 partial remission (PR) cases and 15 complete remission (CR) cases after immunosuppressive therapy (IST). GDF11 serum levels were assessed by an enzyme-linked immunosorbent assay. GDF11 mRNA expression in peripheral blood mononuclear (PBMNC) was detected through real time polymerase chain reaction. The correlation between GDF11 expression and erythropoietic function was evaluated. RESULTS: The serum GDF11 levels in untreated AA patients were higher than that of the control group. The serum GDF11 levels of PR patients or CR patients after IST was decreased, compared with untreated patients, but did not recover back to the normal levels. GDF11 levels had a negative correlation with hemoglobin (Hb) levels and reticulocyte counts in AA patients. GDF11 levels did not correlate with age, sex and severity of in AA patients. CONCLUSION: Serum GDF11 levels were increased and negatively correlated with Hb levels and reticulocyte counts in AA patients. This suggests an impaired GDF11 response contributing to anemia in AA patients.


Subject(s)
Anemia, Aplastic/blood , Bone Morphogenetic Proteins/blood , Gene Expression Regulation , Growth Differentiation Factors/blood , Leukocytes, Mononuclear/metabolism , Adolescent , Adult , Aged , Anemia, Aplastic/pathology , Anemia, Aplastic/therapy , Child , Female , Humans , Immunosuppression Therapy , Leukocytes, Mononuclear/pathology , Male , Middle Aged , Reticulocyte Count
2.
Cell Physiol Biochem ; 51(6): 2925-2937, 2018.
Article in English | MEDLINE | ID: mdl-30580328

ABSTRACT

BACKGROUND/AIMS: Jagged1 is the ligands of the Notch signaling and has been shown to promote glioma-initiating cells (GICs) in glioblastoma. The role of Jagged1 in GICs invasion and underlying molecular mechanisms remain unclear. METHODS: Survival data from R2 genomics analysis, the Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA) and visualization platform database were used to evaluate the effects of Jagged1 on overall patient survival. we investigated Jagged1 induced the GICs cells' invasion by matrix degradation assays and Transwell cell invasion assays in vitro, then we further explored the underlying molecular mechanisms using Co-immunoprecipitation (co-IP) analysis. RESULTS: High expression of Jagged1 in human glioma was associated with poor survival. Clinical data analysis showed that the Jagged1 was positively correlated with NF-κB(p65). Jagged1-induced invasion of GICs cells through activation of NF-κB(p65) pathway. In vivo, knockdown of Jagged1 could suppress the tumorigenicity of GICs cells through NF-κB(p65) signaling. CONCLUSION: Insights gained from these findings suggest that Jagged1 plays an important oncogenic role in GICs malignancy by activation of NF-κB(p65) signaling, and Jagged1 could be employed as an effective therapeutic target for GICs.


Subject(s)
Brain Neoplasms/genetics , Glioma/genetics , Jagged-1 Protein/genetics , Neoplasm Invasiveness/genetics , Signal Transduction , Transcription Factor RelA/metabolism , Animals , Brain Neoplasms/diagnosis , Brain Neoplasms/metabolism , Brain Neoplasms/pathology , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Gene Silencing , Glioma/diagnosis , Glioma/metabolism , Glioma/pathology , Humans , Jagged-1 Protein/analysis , Jagged-1 Protein/metabolism , Mice, Inbred BALB C , Mice, Nude , Neoplasm Invasiveness/diagnosis , Neoplasm Invasiveness/pathology , Prognosis , Up-Regulation
3.
Oncol Rep ; 40(1): 463-471, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29749548

ABSTRACT

Glioblastoma multiforme (GBM) is a fatal cancer with varying life expectancy, even for patients undergoing the same standard therapy. Identification of differentially expressed genes in GBM patients with different survival rates may benefit the development of effective therapeutic strategies. In the present study, key pathways and genes correlated with survival in GBM patients were screened with bioinformatic analysis. Included in the study were 136 eligible patients who had undertaken surgical resection of GBM followed by temozolomide (TMZ) chemoradiation and long-term therapy with TMZ. A total of 383 differentially expressed genes (DEGs) related to GBM survival were identified. Gene Ontology and pathway enrichment analysis as well as hub gene screening and module analysis were performed. As expected, angiogenesis and migration of GBM cells were closely correlated with a poor prognosis. Importantly, the results also indicated that cell dormancy was an essential contributor to the reduced survival of GBM patients. Given the lack of specific targeted genes and pathways known to be involved in tumour cell dormancy, we proposed enriched candidate genes related to the negative regulation of cell proliferation, signalling pathways regulating pluripotency of stem cells and neuroactive ligand-receptor interaction, and 3 hub genes (FTH1, GRM1 and DDIT3). Maintaining persistent cell dormancy or preventing tumour cells from entering dormancy during chemoradiation should be a promising therapeutic strategy.


Subject(s)
Antineoplastic Agents, Alkylating/administration & dosage , Dacarbazine/analogs & derivatives , Glioblastoma/drug therapy , Neovascularization, Pathologic/drug therapy , Adolescent , Adult , Aged , Cell Movement/drug effects , Cell Proliferation/drug effects , Cell Proliferation/radiation effects , Combined Modality Therapy , Dacarbazine/administration & dosage , Disease-Free Survival , Female , Ferritins/genetics , Gene Expression Regulation, Neoplastic/drug effects , Gene Expression Regulation, Neoplastic/radiation effects , Glioblastoma/genetics , Glioblastoma/pathology , Glioblastoma/radiotherapy , Humans , Male , Middle Aged , Neovascularization, Pathologic/genetics , Neovascularization, Pathologic/pathology , Neovascularization, Pathologic/radiotherapy , Oxidoreductases , Temozolomide , Transcription Factor CHOP/genetics , Young Adult
4.
Mol Med Rep ; 18(1): 741-748, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29767255

ABSTRACT

Glioblastoma multiforme (GBM) is one of the most lethal types of tumour, despite severe treatment methods. The Cancer Genome Atlas has categorised GBMs into proneural, neural, classical and mesenchymal subtypes; the mesenchymal subgroup has the worst prognosis. CXCR4 has been reported as selectively overexpressed in the mesenchymal subtype and positively associated with MES markers. However, to the best of our knowledge the underlying mechanisms regarding how CXCR4 may regulate mesenchymal GBM are still unknown. The present study aimed to investigate the critical pathways mediated by CXCR4 in mesenchymal GBM using bioinformatic analyses. The results suggested that CXCR4 is a predictor of poor prognosis and may serve as a biomarker of the mesenchymal subtype in patients with GBM. In addition, CXCR4 mediated the mitogen­activated protein kinase signaling pathway, which was identified specifically in patients with mesenchymal GBM. CXCR4 associated genes or pathways may be a 'basket trial' option for the management of melanoma, prostate cancer and mesenchymal GBM.


Subject(s)
Biomarkers, Tumor , Brain Neoplasms , Computational Biology , Glioblastoma , Mesoderm , Neoplasm Proteins , Receptors, CXCR4 , Signal Transduction/genetics , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Brain Neoplasms/genetics , Brain Neoplasms/metabolism , Brain Neoplasms/mortality , Brain Neoplasms/pathology , Databases, Genetic , Disease-Free Survival , Female , Glioblastoma/genetics , Glioblastoma/metabolism , Glioblastoma/mortality , Glioblastoma/pathology , Humans , Male , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Receptors, CXCR4/genetics , Receptors, CXCR4/metabolism , Survival Rate
5.
J Trace Elem Med Biol ; 47: 89-97, 2018 May.
Article in English | MEDLINE | ID: mdl-29544812

ABSTRACT

OBJECTIVE: Our aim was to investigate thyroid function alterations attributed to high iodide supplementation in maternal rats and their offspring. METHODS: Depending on their iodide intake, the pregnant rats were randomly divided into three groups: normal iodide intake (NI), 10 times high iodide intake (10 HI) and 100 times high iodide intake (100 HI) groups. Iodine concentration in the urine and maternal milk; iodine content and mitochondrial superoxide production; expression of TRα1, TRß1, NIS and Dio1 in both the thyroid and mammary glands were all measured. The offspring were exposed to different iodide-containing water (NI, 10 HI and 100 HI) from weaning to postnatal day 180 (PN180). Serum thyroid hormone levels were measured in both maternal rats and their offspring. RESULTS: Iodine concentration in the urine and maternal milk, as well as iodine content in the thyroid and mammary glands was significantly increased in both the 10 HI and 100 HI groups (p < .05). In the 100 HI group of maternal rats, low FT3 levels, high FT4, TPOAb and TgAb levels were detected. In addition, an increased mitochondrial superoxide production and decreased expression of TRα1, TRß1, NIS and Dio1 in the thyroid and mammary glands was found (p < .05). A positive staining of CD4+ that co-localized with TRß1 in the infiltrated cells within the thyroid follicles was observed. At PN180 in the offspring, the FT3 and FT4 levels showed a significant decrease, while the levels of serum TSH, TPOAb and TgAb were significantly increased in both 10 HI and 100 HI groups (p < .05). CONCLUSION: In maternal rats, although normal thyroid function can be maintained following 10 HI, thyroiditis can be induced following 100 HI on lactation days 7, 14, and 21. In the offspring at PN180, hypothyroidism complicated with thyroiditis can occur in both the 10 HI and 100 HI groups.


Subject(s)
Iodine/administration & dosage , Mammary Glands, Animal/drug effects , Thyroid Gland/drug effects , Animals , Animals, Newborn , Female , Hypothyroidism/chemically induced , Iodide Peroxidase/genetics , Iodine/analysis , Iodine/urine , Male , Mammary Glands, Animal/metabolism , Milk/chemistry , Rats, Wistar , Receptors, Thyroid Hormone/genetics , Superoxides/metabolism , Thyroid Function Tests , Thyroid Gland/physiology , Thyroxine/analysis , Triiodothyronine/analysis
6.
Cell Death Dis ; 9(3): 292, 2018 02 20.
Article in English | MEDLINE | ID: mdl-29463791

ABSTRACT

Numerous studies have shown that calmodulin (CaM) is a major regulator of calcium-dependent signaling, which regulates cell proliferation, programmed cell death, and autophagy in cancer. However, limited information is available on mechanisms underlying the effect of CaM on the invasive property of glioblastoma multiforme (GBM) cells, especially with respect to invadopodia formation. In this study, we find that CaM serves as a prognostic factor for GBM, and it is strongly associated with the invasive nature of this tumor. Results of preliminary experiments indicated that CaM concentration was significantly correlated with the invasive capacity of and invadopodia formation by different GBM cell lines. CaM inhibition via a small hairpin RNA or a pharmacological inhibitor significantly disrupted invadopodia formation and MMP activity and downregulated vimentin expression. Moreover, CaM knockdown exerted a strong anti-invasive effect on GBM in vivo. Interestingly, epidermal growth factor treatment promoted CaM redistribution from the nucleus to the cytoplasm, eventually activating invadopodia-associated proteins by binding to them via their cytosolic-binding sites. Moreover, CaM inhibition suppressed the activation of invadopodia-associated proteins. Thus, our findings provide a novel therapeutic strategy to impede GBM invasion by inhibiting invadopodia formation, and shed light on the spatial organization of CaM signals during GBM invasion.


Subject(s)
Brain Neoplasms/metabolism , Calmodulin/metabolism , Glioblastoma/metabolism , Podosomes/metabolism , Brain Neoplasms/genetics , Brain Neoplasms/pathology , Calcium/metabolism , Calmodulin/genetics , Cell Line, Tumor , Epidermal Growth Factor/metabolism , Glioblastoma/genetics , Glioblastoma/pathology , Humans , Neoplasm Invasiveness , Protein Transport , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Vimentin/genetics , Vimentin/metabolism
7.
Oxid Med Cell Longev ; 2017: 4383652, 2017.
Article in English | MEDLINE | ID: mdl-28133506

ABSTRACT

Wistar rats were randomly divided into groups of varying iodide intake: normal iodide; 10 times high iodide; and 100 times high iodide on Days 7, 14, and 28. Insignificant changes were observed in thyroid hormone levels (p > 0.05). Urinary iodine concentration and iodine content in the thyroid glands increased after high consumption of iodide from NI to 100 HI (p < 0.05). The urinary iodine concentration of the 100 HI group on Days 7, 14, and 28 was 60-80 times that of the NI group. The mitochondrial superoxide production and expressions of Nrf2, Srx, and Prx 3 all significantly increased, while Keap 1 significantly decreased in the 100 HI group when compared to the NI or 10 HI group on Days 7, 14, and 28 (p < 0.05). Immunofluorescence staining results showed that Nrf2 was localized in the cytoplasm in NI group. Although Nrf2 was detected in both cytoplasm and nucleus in 10 HI and 100 HI groups, a stronger positive staining was found in the nucleus. We conclude that the activation of the Nrf2-Keap 1 antioxidative defense mechanism may play a crucial role in protecting thyroid function from short-term iodide excess in rats.


Subject(s)
Iodides/toxicity , Kelch-Like ECH-Associated Protein 1/metabolism , NF-E2-Related Factor 2/metabolism , Thyroid Gland/metabolism , Animals , Blotting, Western , Flow Cytometry , Fluorescent Antibody Technique , Rats , Rats, Wistar , Signal Transduction/drug effects , Thyroid Gland/drug effects , Thyroid Hormones/metabolism
8.
Endocrinol Metab (Seoul) ; 31(1): 174-84, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26754589

ABSTRACT

BACKGROUND: Increased oxidative stress has been suggested as one of the underlying mechanisms in iodide excess-induced thyroid disease. Metallothioneins (MTs) are regarded as scavengers of reactive oxygen species (ROS) in oxidative stress. Our aim is to investigate the effects of propylthiouracil (PTU), a thyroid peroxidase inhibitor, perchlorate (KClO4), a competitive inhibitor of iodide transport, and thyroid stimulating hormone (TSH) on mitochondrial superoxide production instigated by high concentrations of iodide in the thyroids of MT-I/II knockout (MT-I/II KO) mice. METHODS: Eight-week-old 129S7/SvEvBrd-Mt1(tm1Bri) Mt2(tm1Bri)/J (MT-I/II KO) mice and background-matched wild type (WT) mice were used. RESULTS: By using a mitochondrial superoxide indicator (MitoSOX Red), lactate dehydrogenase (LDH) release, and methyl thiazolyl tetrazolium (MTT) assay, we demonstrated that the decreased relative viability and increased LDH release and mitochondrial superoxide production induced by potassium iodide (100 µM) can be relieved by 300 µM PTU, 30 µM KClO4, or 10 U/L TSH in the thyroid cell suspensions of both MT-I/II KO and WT mice (P<0.05). Compared to the WT mice, a significant decrease in the relative viability along with a significant increase in LDH release and mitochondrial superoxide production were detected in MT-I/II KO mice(P<0.05). CONCLUSION: We concluded that PTU, KClO4, or TSH relieved the mitochondrial oxidative stress induced by high concentrations of iodide in the thyroids of both MT-I/II KO and WT mice. MT-I/II showed antioxidant effects against high concentrations of iodide-induced mitochondrial superoxide production in the thyroid.

SELECTION OF CITATIONS
SEARCH DETAIL
...